These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25394000)

  • 1. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.
    Rokx C; Fibriani A; van de Vijver D; Verbon A; Schutten M; Gras L; Rijnders BJ
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19491. PubMed ID: 25394000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
    Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
    HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
    Chetty T; Thorne C; Coutsoudis A
    PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.
    Rokx C; Fibriani A; van de Vijver DA; Verbon A; Schutten M; Gras L; Rijnders BJ;
    Clin Infect Dis; 2015 Jan; 60(1):143-53. PubMed ID: 25273080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
    Tang MW; Kanki PJ; Shafer RW
    Clin Infect Dis; 2012 Mar; 54(6):862-75. PubMed ID: 22357809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
    de Boissieu P; Dramé M; Raffi F; Cabie A; Poizot-Martin I; Cotte L; Garraffo R; Delobel P; Huleux T; Rey D; Bani-Sadr F;
    Medicine (Baltimore); 2016 Sep; 95(37):e4890. PubMed ID: 27631261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
    Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
    HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
    Rogatto F; Bouee S; Jeanbat V; Piontkowsky D; Aragao F; Bosse M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19605. PubMed ID: 25394109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes.
    Caniglia EC; Zash R; Jacobson DL; Diseko M; Mayondi G; Lockman S; Chen JY; Mmalane M; Makhema J; Hernán MA; Shapiro RL
    AIDS; 2018 Jan; 32(1):113-120. PubMed ID: 29112066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
    Jing C; Wei T; Ning W; Fang Z; Gang X; Xingzhi W; Guoqiang Z; Min W
    BMC Infect Dis; 2023 Jun; 23(1):396. PubMed ID: 37308847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
    Omeje I; Okwundu CI
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007276. PubMed ID: 22336829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
    JAMA Pediatr; 2017 Oct; 171(10):e172222. PubMed ID: 28783807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
    Bulteel N; Bansi-Matharu L; Churchill D; Dunn D; Bibby D; Hill T; Sabin C; Nelson M; ;
    J Infect; 2014 Jan; 68(1):77-84. PubMed ID: 24055802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
    Elzi L; Erb S; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M;
    Arch Intern Med; 2012 Sep; 172(17):1313-21. PubMed ID: 22892835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.